- Abstract viewed - 2400 times
- PDF downloaded - 1708 times
- Untitled downloaded - 0 times
- Untitled downloaded - 0 times
Copyright
© Clujul Medical, 2019
Affiliations
Olga Hilda Orasan
Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca
George Ciulei
Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca
Angela Cozma
Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca
Madalina Sava
Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca
Dan Lucian Dumitrascu
Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca
How to Cite
Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologies
Abstract
Chronic liver diseases represent a significant public health problem worldwide. The degree of liver fibrosis secondary to these diseases is important, because it is the main predictor of their evolution and prognosis.
Hyaluronic acid is studied as a non-invasive marker of liver fibrosis in chronic liver diseases, in an attempt to avoid the complications of liver puncture biopsy, considered the gold standard in the evaluation of fibrosis. We review the advantages and limitations of hyaluronc acid, a biomarker, used to manage patients with chronic viral hepatitis B or C infection, non-alcoholic fatty liver disease, HIV-HCV coinfection, alcoholic liver disease, primary biliary cirrhosis, biliary atresia, hereditary hemochromatosis and cystic fibrosis.